📄 Redirect examination of Dr. Robin Cotton (part 1) — Monday, May 15, 1995
Address:
C:\DEPT103\CRIMINAL\1995\MAY\15\REDIRECT-EXAMINATION-OF-DR-ROB.DOC
TRIAL
▲ Day 74 of 167

Redirect examination of Dr. Robin Cotton (part 1)

Witness: Dr. Robin Cotton
Examiner: George Clarke
Called by: Prosecution • Date: Monday, May 15, 1995 • Utterances: 649
George Clarke conducted redirect examination of DNA expert Dr. Robin Cotton, methodically dismantling defense cross-contamination hypotheticals posed by Peter Neufeld. Clarke walked Cotton through yield gel photographs showing different levels of DNA degradation across the Bundy walkway blood drops, establishing that the varying DNA quality among items 47-52 was inconsistent with a single contamination event. Cotton also confirmed the lab's clean proficiency testing record (104 tests, 466 samples, zero false positives since 1989) and corrected a morning error regarding which item triggered a positive reagent blank control.
1 THE COURT:

Thank you, ladies and gentlemen. Please be seated. The record should reflect that we have been rejoined by all the members of our jury panel. Dr. Cotton, would you resume the witness stand. And, Mr. Clarke, you may redirect.

2 MR. CLARKE:

Thank you, your Honor. Good afternoon again, ladies and gentlemen.

THE JURY: Good afternoon.

REDIRECT EXAMINATION BY MR. CLARKE

3 MR. CLARKE:

Dr. Cotton, with regard to these proficiency tests that you were asked questions about earlier today, can you estimate for us or otherwise tell us the number of proficiency tests that your laboratory has taken since 1989?

4 DR. COTTON:

I made a count, assuming I counted correctly, since the beginning of 1990 till the end of 1993, comes to about 104, and there have been ongoing tests in 1994 and continuing into `95, but they're not reflected in the documentation I have with me. So I didn't include those.

5 MR. CLARKE:

Now, is that just the number of different tests that the laboratory has taken, proficiency tests?

6 DR. COTTON:

That's right.

7 MR. CLARKE:

And I believe you said that was through 1993?

8 DR. COTTON:

Yes.

9 MR. CLARKE:

Is there any way you can estimate the number of tests, for instance, in 1994?

10 MR. NEUFELD:

Objection. Hearsay and discovery.

11 THE COURT:

Overruled. Excuse me. Sustained on the--as to speculation, asking to estimate.

12 MR. CLARKE:

All right.

13 MR. CLARKE:

With regard to these--and I'm sorry. What was the number again since 1989 through 1993?

14 DR. COTTON:

I counted 104.

15 MR. CLARKE:

How many different samples--do you have a count of the total number of different samples that those 100 plus tests included?

16 DR. COTTON:

Yes, I do.

17 MR. CLARKE:

How many is that?

18 DR. COTTON:

466.

19 MR. CLARKE:

Of those 466 samples since 1989, that is proficiency test samples that have been tested, how many errors has the laboratory made?

20 DR. COTTON:

There are no false positives and no incorrect exclusions in the remainder of those samples since 1989.

KEY QUOTE
21 MR. CLARKE:

Since 1989, has your laboratory made or have they typed any false positives in any test?

22 DR. COTTON:

Well, I can only--I can only tell you what we're aware of and--

23 MR. NEUFELD:

Objection. Objection. It's speculation at that point, your Honor.

24 THE COURT:

Overruled.

25 DR. COTTON:

Obviously--

26 THE COURT:

She said, "Only that I'm aware of." That's not speculation. Proceed.

27 MR. NEUFELD:

Your Honor, may I just ask for clarification? Is this proficiency testing? I just--

28 THE COURT:

Proceed.

29 MR. CLARKE:

I'm sorry. Could the witness be allowed to conclude her answer? I believe she was in mid sentence.

30 THE COURT:

Yes, she was.

31 DR. COTTON:

The only measure we have of a false positive or a false exclusion is on a proficiency test. I obviously can not tell you in a case because we--as was pointed out earlier, we don't know what the result is supposed to be. I can't tell you whether in the number of cases that we done--have done, whether there are any because although it's possible you would be able to pick it out, it's not a guarantee that you would be able to pick it out by any stretch. And, therefore, I can only tell you in reference to the proficiency tests, and I can't tell you any further than that.

32 MR. CLARKE:

Perhaps I misspoke. Actually I was addressing myself only to proficiency tests and those tests that you've taken since 1989.

33 DR. COTTON:

There are no false--additional false positives and there are no incorrect exclusions in the proficiency tests since 1989.

34 MR. CLARKE:

Incidentally, as far as this area of proficiency testing, what role if any did your proficiency tests have to do with your accreditation by the American Society of Crime Laboratory Directors?

35 DR. COTTON:

Like the TWGDAM guidelines, the ASCLAD lab requires that each analyst take two tests per year, and one of them must be from an approved--an ASCLAD approved proficiency test provider. And we must sign documentation agreeing with--that we will give those results back to a committee--back to ASCLAD--it's a committee within ASCLAD lab--for their review. So not only are they being reviewed by our laboratory, but they're being reviewed by ASCLAD.

36 MR. CLARKE:

Was this or did these proficiency tests play any role in your accreditation process?

37 DR. COTTON:

We--if we had not been doing the level of proficiency testing that we have, our lab would not have been accredited.

38 MR. CLARKE:

And it was accredited; is that right?

39 DR. COTTON:

Yes.

40 MR. CLARKE:

Now, I'd like to change topics to--and do you recall a series of hypothetical questions asked you by Mr. Neufeld about various swatches taken from the Bundy crime scene?

41 DR. COTTON:

Yes, I do.

42 MR. CLARKE:

And in particular, do you recall being asked questions about the various blood drops starting from the drop closest to the victims' bodies, no. 47, through and including the remaining drops, 48, 49, 50, and then finally 52 out in the driveway area?

43 DR. COTTON:

Yes.

44 MR. CLARKE:

Do you recall his questioning you about the possibility that each and every one of those samples was cross-contaminated by contact with swatches taken at a different scene; mainly, the Rockingham home?

45 DR. COTTON:

Yes, I do.

46 MR. CLARKE:

First of all, how can DNA get from one swatch on to another swatch by contact?

47 DR. COTTON:

If both swatches were wet and they were in immediate contact with each other presumably because they were wet, you could have some exchange of material. If they were dry, that would be harder and you might have to have sort of an excess of material on the swatch, such that some was basically sort of flaking off. But it would be harder if they were dry than if they were wet.

48 MR. CLARKE:

Now, I believe you described during your cross-examination that that type of transfer from one swatch from one location, that is seized at one location, to another location seized from another location was scientifically possible; is that right?

49 DR. COTTON:

Yes. I'm--there's--I can't say that it's impossible.

50 MR. CLARKE:

Would it be the case--and first of all, you have already testified about various results from the Bundy crime scene; is that right?

51 DR. COTTON:

Yes.

52 MR. CLARKE:

That included this series of blood drops, items 47 through 52?

53 DR. COTTON:

Yes.

54 MR. CLARKE:

Except for item 51 I believe was not one of those particular samples, correct?

55 DR. COTTON:

Yes.

56 MR. CLARKE:

And you described, for instance, typing results from the shoeprint, which is item 56?

57 DR. COTTON:

Yes.

58 MR. CLARKE:

As well as the boot drop, item no. 78. Do you recall that?

59 DR. COTTON:

Yes.

60 MR. CLARKE:

Now, your Honor, with the Court's permission, I would like to use the Bundy results board at this time. And I believe that's People's exhibit 259.

61 (Brief pause.)
62 THE COURT:

Deputy Smith, why don't you grab that other--I think we need it up just a bit. Great. Thank you.

63 MR. CLARKE:

Now, Dr. Cotton, can you see those results without--we won't be going into the individual types and their results, but can you see basically each of those item numbers beginning with 47 from where you're seated?

64 DR. COTTON:

No. I'd better step down.

65 MR. CLARKE:

Well, let me just try it a different way.

66 DR. COTTON:

Okay.

67 MR. CLARKE:

Let's start with item no. 47, the first drop by the victims. And what I'm going to ask you is, for the hypothetical, this hypothetical possibility of a transfer occurring from one set of swatches seized at one location to these particular set of swatches, would it be correct that these individual items, first of all, would have to be collected; in other words, collected by some evidence collector at the Bundy crime scene? Let's start with item 47.

68 DR. COTTON:

Yes.

69 MR. CLARKE:

For that hypothetical to be true about this cross-contamination, would the DNA in that particular sample, again, the first drop by the victims, no. 47, have to degrade to the point that you could detect no DNA whatsoever even by PCR?

70 DR. COTTON:

Yes.

71 MR. CLARKE:

Would that item in terms of the swatch or swatches for each individual item then have to come into contact with these swatches from a totally different scene and a different item number?

72 DR. COTTON:

Yes.

73 MR. CLARKE:

And again, what type of contact would be needed for this to happen?

74 DR. COTTON:

Very--very close contact.

75 MR. CLARKE:

What do you mean by that?

76 DR. COTTON:

Well, they basically have to be right on top--they would have to be touching.

77 MR. CLARKE:

Physically touching?

78 DR. COTTON:

Physically touching.

79 MR. CLARKE:

Is touching enough or does something have to physically happen from one swatch to the other swatch?

80 DR. COTTON:

Well, let's put it this way. Touching is the minimum.

81 MR. CLARKE:

What actually has to transfer from one swatch to the next swatch for this hypothetical to actually be true?

82 DR. COTTON:

Well, given that the swatches are bloodstains, white blood cells have to transfer--I mean, you wouldn't have just white, but you would have to have blood cells transferring off one swatch and on to the other.

83 MR. CLARKE:

What would have to be the quantity and quality of these cells that have gone from one swatch to the other swatch so that you could only detect the material that transferred?

84 DR. COTTON:

The material on the swatch from which the contamination was coming would have to be of sufficient quantity and quality to do the testing--to appear on the final test. So given that one now had completely degraded so you couldn't test it, you would have to have enough transfer from the other swatch, enough DNA of sufficient quality to be able to now see it on the test.

85 MR. CLARKE:

And then ultimately--and you've described that final step. Ultimately, for this hypothetical to be true, you would then have to go through a typing process and only detect the types from the swatches that supposedly cross-contaminated, for instance, item no. 47?

86 DR. COTTON:

Yes.

87 MR. CLARKE:

Now, would that same occurrence for this hypothetical to be true have to have happened to item no. 48, the next Bundy walkway drop?

88 DR. COTTON:

Yes.

89 MR. CLARKE:

As well as 49, the next drop?

90 DR. COTTON:

Yes.

91 MR. CLARKE:

50, the next drop?

92 DR. COTTON:

Yes.

93 MR. CLARKE:

And 52, the next drop?

94 DR. COTTON:

Yes.

95 MR. CLARKE:

Now, let's talk in a little bit more detail about item no. 52. What do we know about the quantity and quality in item no. 52 in comparison to 47, 48, 49 and 50, the earlier drops on the walkway?

96 DR. COTTON:

We know that the quality of the DNA in 52 is sufficiently good to give an RFLP banding pattern. That is, some of the DNA is good enough to do that. And it--and you can--you can see on the mini gel that it's much better than the 49 and 50 which were also run on mini gels. And then as far as 47 and 48, that--that was not good enough either. So basically 52 is in much better shape than 47, 48, 49 and 50.

97 MR. CLARKE:

Does that mean the DNA transferred by this hypothetical from another swatch at another scene to the material in item no. 52 would have to be some amount in quality of DNA in excess of the remaining drops?

98 DR. COTTON:

Yes.

99 MR. CLARKE:

Is there any way to describe that difference in how much and what the quality of the DNA would have to be?

100 DR. COTTON:

Well, in terms of quality, it would--there is a sub--I'm--I have a very good recollection of what 49 and 50 look like for some reason. So I'll just use those as an example. The difference in the level of degradation between 49 and--49 and 50 look about the same, and they are very different from 52. In terms of quantity of DNA in those samples, I would have to go back into the case folder and look at the amounts and give you--to give you a good estimate.

101 MR. CLARKE:

Okay. In any event, it would be greater than the remaining samples, 47 through 50, that would have to be transferred in the hypothetical? I'm referring to the quality and quantity of DNA.

102 DR. COTTON:

In terms of the quantity, are you saying is that different for 52 than the others?

103 MR. CLARKE:

Correct. What you are able to actually detect.

104 DR. COTTON:

In terms of what you can detect, yes. In terms of actual mass amount, it may not be any different.

105 MR. CLARKE:

In other words, the actual size of what was on the swatch?

106 DR. COTTON:

The actual weight, that is of the DNA that you have, which is measured in terms of nanograms, it could be a similar amount in 49 and 50, for example. It's just that it's very degraded and the other is not.

107 MR. CLARKE:

Okay. Now I would like to turn your attention to item no. 56, the shoeprint that's also listed on this particular Bundy crime scene results board. As far as that particular item is concerned, is there any indication whatsoever of cross-contamination similar to that on 47, 48, 49, 50 and 52 in terms of DNA type?

108 DR. COTTON:

No.

109 MR. CLARKE:

Why? What's the difference?

110 DR. COTTON:

Well, the other--47, 48, 49 and 50 are consistent in type with Mr. Simpson. 56 is consistent in type with Nicole Brown. So if all of those samples were contaminated, they couldn't have all been contaminated from the same source.

KEY QUOTE
111 MR. CLARKE:

Because the types are different; is that right?

112 DR. COTTON:

Yes.

113 MR. CLARKE:

And in fact, at least one of them--let's take the DQ-Alpha alleles. Is it true that there is one DQ-Alpha type that's not even present in item no. 56, the shoeprint?

114 DR. COTTON:

You mean that is present in the other samples--

115 MR. CLARKE:

Yes.

116 DR. COTTON:

Yes.

117 MR. CLARKE:

And what's that?

118 DR. COTTON:

It's the 1.2 allele.

119 MR. CLARKE:

Now, with regard to this hypothetical--and first of all--well, let me rephrase that question. With regard to this hypothetical, do these unstained controls play any role in determining whether or not this type of transfer could have occurred?

120 DR. COTTON:

Well, they would if they were out and about at the same time that you're postulating the other contamination occurred because they don't have any DNA on them, the ones that we tested.

121 MR. CLARKE:

All right. Let me put it in a form--I'm sorry. I interrupted you.

122 DR. COTTON:

I'm finished.

123 MR. CLARKE:

Let me put it in the form of a hypothetical to you. If those unstained controls--and let's assume there are unstained controls for these various items of evidence, 47, et cetera--and that those were processed in the same manner as the bloodstains, would those unstained controls in terms of if they detected no DNA, typeable DNA, provide you any information about whether or not this hypothetical cross-contamination transfer actually occurred?

124 MR. NEUFELD:

Objection.

125 THE COURT:

Basis?

126 MR. NEUFELD:

Well, part of the objection is the "et cetera." I mean, maybe he should spell out which samples he's referring to.

127 THE COURT:

Sustained.

128 MR. CLARKE:

All right. Instead of that et cetera, 47, 48, 49, 50 and 52. Do the unstained controls provide you any further information if what I described to you is the case?

129 MR. NEUFELD:

Objection. Assumes facts not in evidence.

130 THE COURT:

Overruled.

131 DR. COTTON:

If the unstained controls were processed in the same manner at the same time as the actual samples, then you would have to postulate that the contamination only occurred on the actual samples and didn't occur on the unstained controls. So it would be a very specific contamination, not just sort of affecting everything.

132 MR. CLARKE:

And by "processed at the same time," do you mean collected, allowed to dry, repackaged, et cetera?

133 DR. COTTON:

That's--yes, I do.

134 MR. CLARKE:

That's the second time I've used the word "et cetera." But through those stages that I just described including packaging?

135 DR. COTTON:

Yes.

136 MR. CLARKE:

Do these unstained controls in this case represent or are they an additional safeguard as to the accuracy of DNA results in this case?

137 MR. NEUFELD:

Objection. No foundation for this witness.

138 THE COURT:

Overruled.

139 DR. COTTON:

The unstained controls tell you one thing. That is, that there was no DNA on a spot adjacent to where the stain was lifted from. I don't think they say anything beyond that.

140 MR. CLARKE:

Are these unstained controls, are they to show the presence or absence of bacteria? Is that what you use them for, for instance?

141 DR. COTTON:

No. We don't have--I suppose you could test for the presence of bacteria on those unstained controls. We don't--

142 MR. NEUFELD:

Objection. Move to strike, "suppose," because she's speculating at this point.

143 THE COURT:

Overruled.

144 DR. COTTON:

We don't have the capability in our lab of doing that.

145 MR. CLARKE:

Incidentally, in your laboratory, in the controls that you tested, that included item no. 49, that is an actual unstained substrate control for one of the Bundy walk stains, no. 49?

146 MR. NEUFELD:

Objection. Inconsistent with the testimony.

147 THE COURT:

Overruled.

148 DR. COTTON:

Can I check my book?

149 MR. CLARKE:

Sure. Please do.

150 (The witness complies.)
151 THE COURT:

There's no designation of 49-C though as I recollect.

152 MR. CLARKE:

I'm sorry?

153 THE COURT:

There's no designation of 49-C.

154 DR. COTTON:

We received a sample, was labeled item no. 49. It was sent to us with other samples that were indicated that they were unstained controls. It didn't have "C" or control written after it.

155 MR. CLARKE:

And did you test that particular item for its DNA content?

156 DR. COTTON:

Yes, we did.

157 MR. NEUFELD:

Objection, your Honor. Misstates the evidence. Can I have a sidebar?

158 THE COURT:

Overruled. No.

159 MR. CLARKE:

With what result?

160 DR. COTTON:

Uh, it didn't produce any type.

161 MR. CLARKE:

And when you say "No DNA type," what do you mean?

162 DR. COTTON:

We got no detectable typeable DNA from that sample.

163 MR. CLARKE:

Now, you also tested other unstained controls; is that right?

164 DR. COTTON:

Yes.

165 MR. CLARKE:

What Los Angeles Police Department item numbers were those?

166 DR. COTTON:

Item 7 control, item 12 control, item 49, doesn't say control after it, item 56, doesn't say control after it.

167 MR. NEUFELD:

Move to strike the earlier testimony as to 49, a control.

168 THE COURT:

Overruled.

169 MR. CLARKE:

With what results for the other three? You're already described 49.

170 DR. COTTON:

No detectable, no typeable, DNA was present.

171 MR. CLARKE:

Are you aware that any other unstained controls were tested by any other laboratories in this case?

172 MR. NEUFELD:

Objection. Hearsay.

173 THE COURT:

Sustained.

174 (Discussion held off the record between the Deputy District Attorneys.)
175 MR. CLARKE:

Dr. Cotton, I would like to offer you a hypothetical. That if in fact, with regard to these particular items at the crime scene, that is the Bundy crime scene--actually, let me rephrase that.

176 MR. CLARKE:

May I have just a moment, your Honor?

177 (Discussion held off the record between the Deputy District Attorneys.)
178 MR. CLARKE:

Dr. Cotton, I would like you to assume that with respect to this particular results board, the Bundy results board, that with regard to each of the items, except for purposes of this question, 84-A and 84-B, that there was an unstained control seized for each of those particular items. All right?

179 DR. COTTON:

Okay.

180 MR. CLARKE:

That the results of those unstained controls showed no detectable DNA present. All right?

181 DR. COTTON:

Yes.

182 MR. CLARKE:

Does that information assist you in reaching any opinion about whether or not the cross-contamination possibility posed by Defense counsel occurred in this case?

183 MR. NEUFELD:

Objection. Improper hypothetical. I move to strike.

184 THE COURT:

Sustained.

185 (Discussion held off the record between the Deputy District Attorneys.)
186 MR. CLARKE:

Now, I would like to shift your attention if I could, Dr. Cotton, to questions posed to you about the possibility of a blood tube, that is a tube containing known DNA, could have been spilled or placed or inadvertently mixed with the same swatches, that is from items 47 through 52, the Bundy walkway stains. Do you recall those questions?

187 DR. COTTON:

Yes.

188 MR. CLARKE:

For that to have occurred and for you to have obtained the types that you described, again would the DNA in these various walkway stains have to degrade so that you could detect no DNA? Actually let me rephrase that. Be able to detect no DNA types.

189 DR. COTTON:

Yes.

190 MR. CLARKE:

Would it also be correct for that hypothetical to be true that you would then obtain only the DNA types from this spilled or otherwise contaminated tube blood?

191 DR. COTTON:

Yes.

192 MR. CLARKE:

If this occurred, that is, these spills or placement from a tube, would you expect these particular swatches from 47 through 52 to have the same quantity--let me rephrase that--to have the same quality DNA?

193 DR. COTTON:

There would be a reasonable expectation that if that occurred, they would have close to the same quality of DNA.

194 MR. CLARKE:

Why?

195 DR. COTTON:

Well, I could think of two scenarios. One is, the blood gets on there, it dries, and once it's dried, nothing much happens to it in terms of degradation, in which case you would expect to have the same quality of DNA. The only way I can postulate that that wouldn't be the case would be, the blood gets on the swatches and it doesn't dry very rapidly, and, therefore, something that's already on the swatch then differentially degrades the DNA on one swatch as compared to another; and in that case, you wouldn't obviously expect that they would all be the same.

196 MR. CLARKE:

Did you see, in terms of these stains, the same quality of DNA, this is again the walkway stains, 47 through 52, or did you see differences in quality of DNA?

197 MR. NEUFELD:

Objection as to the word "see" with respect to the quality of DNA.

198 THE COURT:

Sustained. Rephrase the question.

199 MR. CLARKE:

Did you detect or did you determine if the DNA quality from these swatches, 47 through 52, was the same or was it different?

200 DR. COTTON:

It's different.

201 MR. CLARKE:

How? What were the differences?

202 DR. COTTON:

You can see the differences on the mini gel in terms of how degraded the DNA is in those different samples.

203 MR. CLARKE:

Was there a difference--and let's--you know, if this would help you, let's take 47 and 48. Were there differences between those two, or if there's a better way of describing this difference, please tell us how.

204 DR. COTTON:

If you want me to be more precise about it, you'll need to let me get out the pictures so that I can look at them.

205 MR. CLARKE:

All right. If you would.

206 (The witness complies.)
207 DR. COTTON:

Okay. We'll give this a try.

208 MR. CLARKE:

Could you start with item 47 and tell us what would be the easiest way to make this comparison between that first walkway stain by the victims and the remainder?

209 DR. COTTON:

Well, I'll go down item by item and sort of try to give you the level of degradation that we can see on the mini gel versus sort of like not very much, a moderate amount or a lot.

210 MR. CLARKE:

Okay.

211 DR. COTTON:

You have to keep in mind that this mini gel isn't assessing human DNA, it's assessing total DNA, and, therefore, there's--you know, I can only tell you what I can see. I can't tell you anything about whether what I'm--based on this result alone, as to what I'm seeing is human or not. Okay. Item 47--and again, I'm taking a minute because I have to translate numbers here and also count. Item 47 is very degraded. Item--item 49 and 50 are very degraded. Item 56--

212 MR. NEUFELD:

Objection. That's nonresponsive. It's only limited to the drops I believe.

213 DR. COTTON:

What's the--am I just--

214 THE COURT:

Overruled. I'm sorry. Sustained. Correct. It's not one of the blood drops.

215 MR. CLARKE:

Actually what I am going to ask permission to do, your Honor, is to display to the jury just briefly the photographs of each of these items and ask the witness to describe what they mean as far as this opinion.

216 THE COURT:

You mean the photographs of the actual spots at the crime scene?

217 MR. CLARKE:

No. Photographs of the actual test results from determining how much DNA is present.

218 THE COURT:

All right.

219 MR. CLARKE:

Can we do that, first of all, Dr. Cotton?

220 DR. COTTON:

We can if you'll give me just a second to pull out the--what I have to do is give you the originals and then pull out the sheets from my copies that will tell me what samples in what lane.

221 MR. CLARKE:

All right.

222 MR. NEUFELD:

Your Honor, an additional objection based on her testimony that a lot of it isn't even human DNA--

223 MR. CLARKE:

Well, excuse me, your Honor. I believe--

224 THE COURT:

Speaking objection.

225 MR. NEUFELD:

Sorry. May we have a--may we have a sidebar then, your Honor?

226 THE COURT:

No. Proceed.

227 (Discussion held off the record between the Deputy District Attorney and the witness.)
228 THE COURT:

All right. Do you want to show those to Mr. Neufeld as well?

229 MR. CLARKE:

Yes.

230 (Brief pause.)
231 MR. CLARKE:

First of all, Dr. Cotton, do you have copies of these photographs?

232 DR. COTTON:

With me?

233 MR. CLARKE:

Yes.

234 DR. COTTON:

No.

235 MR. CLARKE:

All right. Could we, your Honor, for purposes of this utilize the originals and obtain copies and at some point substitute them? These are I believe--

236 MR. CLARKE:

Are these photographs from your original raw notes?

237 DR. COTTON:

Yes.

238 THE COURT:

All right. Let's go with the originals today.

239 (Discussion held off the record between the Deputy District Attorney and Defense counsel.)
240 MR. CLARKE:

All right. Dr. Cotton, you have given me two pages. Which one would show--that is, which page and which photograph would demonstrate item no. 47, the first drop?

241 DR. COTTON:

This one (Indicating).

242 MR. CLARKE:

The lower photo on a page labeled at the top August 1, `94 or 8-1-94?

243 DR. COTTON:

Yes.

244 MR. CLARKE:

I believe that would be 263, your Honor, referring to the photograph?

245 THE COURT:

All right. People's 263.

246 (Peo's 263 for id = photograph)
247 MR. CLARKE:

Dr. Cotton, showing you a photograph that's now on the screen that will be People's exhibit 263, what's that a photograph of?

248 DR. COTTON:

It's a photograph of the small mini gel that was used to look at the DNA that was extracted from the samples that were loaded on there.

249 MR. CLARKE:

If I give you the pointing arrow and give you the podium, can you describe for the jury, please, what particular lane we're looking at? And then I'll have you describe what this process actually shows.

250 DR. COTTON:

Sure.

251 MR. CLARKE:

First of all, Dr. Cotton, with regard to this photograph, what would you call this photograph? What's it of?

252 DR. COTTON:

It's a photograph of the mini gel using the DNA samples before they were digested with the restriction enzyme.

253 MR. CLARKE:

And what's this mini gel process? What do you use it for?

254 DR. COTTON:

For looking at how degraded the sample DNA is.

255 MR. CLARKE:

Do you ultimately use photography to be able to later review those results?

256 DR. COTTON:

Yes.

257 MR. CLARKE:

Now, is there a way that you can show us--and let's start with--I'm sorry--item no. 47, the first walkway drop. Can you indicate where you would look for results on this photograph?

258 DR. COTTON:

Are we on here? The top of the gel is up here (Indicating) And you see--see--the best place you can--see right here, that little inden--that's an indentation where the sample is loaded and so is this and so is this. And you can't see them quite as well over here, but they go all across the top. So the person who did the work recorded what sample she loaded in this lane and what sample she loaded in this one and this one and so on. And so based on looking at the notes, when you're asking me about a particular item, looking at the notes and seeing in which lane that item was put into the mini gel.

259 MR. CLARKE:

Now, incidentally, is this one of these x-rays or autorads that you had shown to the jury last week?

260 DR. COTTON:

No. This is actually a photograph of this small gel, which is about two inches by three inches, and the gel is sort of opaque and you can see the edge of it right here (Indicating), this black--this was a full-size picture, that is, it had a lot of extra nothing out here, black, because this gel is laid on a light box, but instead of the white light that you see on the light boxes that have been used so far, it's an ultraviolet box. And because the DNA has been stained with a dye, if you were to look at this in color, the places where you see DNA sort of appear a pinkish orange and the gel has this sort of opaque look and then to--before it's put in the case folder, the gel is just trimmed out and the rest of the picture that doesn't contain a gel or anything else is just thrown away.

261 MR. CLARKE:

How do you read this particular photograph to determine approximately how much and what quality of DNA is present in a sample?

262 DR. COTTON:

The photograph is--you can look at it and think about it just in exactly the same way that you think about the DNA on the autoradiograph. The DNA was put into a sample well up here and it moved down in this direction through the gel (Indicating), and these are three controls that are on the gel. This is the same lambda that's loaded on the large gel that we produced the x-ray film from. So this is a hundred nanograms of lambda and this is 50 and this is 25, and it has the same bands that you would see. And the reason this is on there is that we know the size of this top band is 23,000 base pairs; and what we're looking for is if DNA is in good condition, it will be up here because the pieces will be very, very large. As the DNA is more degraded, then you'll begin to see DNA down here (Indicating).

263 MR. CLARKE:

Why is that?

264 DR. COTTON:

Because as it gets more degraded, the pieces are randomly broken up and all of the pieces get smaller and smaller and smaller. So you can see that the DNA in these lanes--and what you're looking at now is this--this--if you were looking at it on a light box, it would be coloration. Here it just appears white because this is a black and white picture. So you're looking at the distribution of the stain DNA from the top to the bottom of the gel. And if you see it all along, then you have some degradation here. To give you an example, this sample right here, whatever it happens to be (Indicating), does not appear to be very degraded at all. It looks very, very good.

265 MR. CLARKE:

Let's take the three, and I believe you described them all as lambda markers, the far right-hand three lanes that have a series of bands in each one?

266 DR. COTTON:

Yes.

267 MR. CLARKE:

Those are controls in this test?

268 DR. COTTON:

They're controls just to say your gel ran as it should and to give us a sense of--of amounts of DNA, although this is not a real quantitative control. Some other laboratories use a cer--a known amount of human DNA in these positions instead of this lambda, and that actually works a little more nicely in terms of quantitation.

269 MR. CLARKE:

Let's go left to right if we can and let's just go to the first lane on the first left. Can you show us where that is?

270 DR. COTTON:

Right here (Indicating).

271 MR. CLARKE:

Now, what's in that lane in this test?

272 DR. COTTON:

Uh, item 78.

273 MR. CLARKE:

And that would be the boot drop; is that right?

274 DR. COTTON:

Right. Obviously it's the DNA from item 78.

275 MR. CLARKE:

What kind of condition was that DNA in?

276 DR. COTTON:

Well, it looks pretty good. There's not a lot of it, but I see DNA here and I see a little bit of a smear coming down (Indicating), but it looks like it would be good enough to load on an RFLP gel.

277 MR. CLARKE:

In other words, from this result, in terms of the relative quality of the DNA, it appeared that an RFLP test might produce results?

278 DR. COTTON:

Yes.

279 MR. CLARKE:

And was that decision in fact made as to the boot drop?

280 DR. COTTON:

Yes.

281 MR. CLARKE:

And that produced the RFLP results that you described last week; is that right?

282 DR. COTTON:

That's right.

283 MR. CLARKE:

What's in the next lane?

284 DR. COTTON:

The next lane over is item 56.

285 MR. CLARKE:

That's the shoeprint?

286 DR. COTTON:

Yes.

287 MR. CLARKE:

And I believe last week, you described that from this evaluation or mini gel or yield gel--first of all, are those all terms used--

288 DR. COTTON:

Yes.

289 MR. CLARKE:

--to describe this photograph and these results?

290 DR. COTTON:

Yes.

291 MR. CLARKE:

You described that it appeared that that would be enough DNA to be able to obtain a DN--I'm sorry--an RFLP result.

292 DR. COTTON:

Yes. It certainly looked like it because you see there's a lot right here (Indicating).

293 MR. CLARKE:

And that turned out not to be true because of the condition of the DNA, that is what type of DNA itself it was; is that right?

294 DR. COTTON:

It turned out not to be true, and we're now making a judgment call that it wasn't true because the DNA that we're seeing is not human. If this were human DNA, we would have seen a very nice RFLP pattern.

295 MR. CLARKE:

Now, going to the next lane, can you point where that is?

296 DR. COTTON:

Yes. Right here (Indicating).

297 MR. CLARKE:

What was in that lane?

298 DR. COTTON:

This is item 52.

299 MR. CLARKE:

Item 52 was the last blood drop out on the driveway area at Bundy?

300 DR. COTTON:

Yes.

301 MR. CLARKE:

What did this result tell you about that blood drop?

302 DR. COTTON:

There's some DNA in this high molecular weight area. But you can see if you follow this down that there is some DNA that's all the way down in here (Indicating). So this sample is degraded. And if you only had this to look at--I mean now we know that it did give an RFLP pattern, but at the time that we looked at this, the assessment was it might, it might not. So we loaded it, but we didn't know if it would give us a result.

303 MR. CLARKE:

You have described earlier, and I believe as to three of the drops in this trail, that the DNA was very degraded when I asked you on the witness stand?

304 DR. COTTON:

Yes.

305 MR. CLARKE:

How would you characterize the result or the condition rather of the DNA with regard to 52, that blood drop in the driveway?

306 DR. COTTON:

Uh, sort of a medium amount of degradation.

307 MR. CLARKE:

Okay. What's the next lane over to the right?

308 DR. COTTON:

Next lane is item 7 from Rockingham.

309 MR. CLARKE:

In the Rockingham driveway drop?

310 DR. COTTON:

Yes.

311 MR. CLARKE:

One of them?

312 DR. COTTON:

Yes.

313 MR. CLARKE:

Okay. And since we're going to stick to the Bundy scene for the moment, what about the next lane over?

314 DR. COTTON:

The next lane over is 47.

315 MR. CLARKE:

Now, tell us about 47 and what you see there.

316 DR. COTTON:

What you see here is that there is no DNA that's visible in this upper area (Indicating). So from that, you would assume that you are not going to get an RFLP pattern from this particular sample. You can see some DNA down here. See this smear that starts about--little more than halfway down and goes all to the--all the way to the bottom (Indicating). If that's human DNA, that's probably going to be good enough to give a PCR result.

317 MR. CLARKE:

And that's in fact the technology you use to type that particular item?

318 DR. COTTON:

Yes.

319 MR. CLARKE:

And for the moment, what is in the next lane?

320 DR. COTTON:

The next lane is item 12.

321 MR. CLARKE:

And that was the Rockingham foyer?

322 DR. COTTON:

Yes.

323 MR. CLARKE:

And what result in terms of the presence of DNA can you determine from this particular test?

324 DR. COTTON:

You can see a lot of DNA right at the top, a little bit of degradation in here (Indicating), but not a lot. And assuming that this is human DNA, you would expect that it would give you a very nice RFLP pattern.

325 MR. CLARKE:

And did it do so when you conducted your RFLP typing?

326 DR. COTTON:

Yes, it did.

327 MR. CLARKE:

Now, incidentally, before we move on, Dr. Cotton, this particular test, these--that ultimately you received the photographs from, this yield gel--I believe you used that term?

328 DR. COTTON:

Yes.

329 MR. CLARKE:

That's done after you actually extract the DNA in your laboratory?

330 DR. COTTON:

Yes.

331 MR. CLARKE:

And these were all extractions that your laboratory did of DNA from the actual swatches sent to you from Los Angeles?

332 DR. COTTON:

Yes.

333 MR. CLARKE:

Okay. Now, could we move on to--what would be the next photograph, to go to the same page that's currently--

334 DR. COTTON:

No. The other page.

335 MR. CLARKE:

The other page? All right.

336 MR. CLARKE:

And, your Honor, could this photograph be marked as People's exhibit 264?

337 THE COURT:

264.

338 (Peo's 264 for id = photograph)
339 MR. CLARKE:

All right. Dr. Cotton, do you have that second page or do I?

340 DR. COTTON:

I do.

341 MR. CLARKE:

Okay. Thank you.

342 MR. CLARKE:

And, your Honor, may this photograph also be placed on the elmo?

343 THE COURT:

Yes. Have you shown that to Mr. Neufeld?

344 MR. CLARKE:

Yes.

345 MR. CLARKE:

Now, Dr. Cotton, is this another yield gel?

346 DR. COTTON:

Yes.

347 MR. CLARKE:

And does it show results as to any of these samples taken at the Bundy crime scene?

348 DR. COTTON:

This one has the samples from 49 and 50.

349 MR. CLARKE:

Could you point those out to us?

350 DR. COTTON:

These are the same controls I just mentioned. 49 was in this lane and 50 was in this lane (Indicating).

351 MR. CLARKE:

Let's start--and again, first of all, were these samples run in your laboratory on a yield gel after your laboratory extracted DNA from these original swatches?

352 DR. COTTON:

Yes.

353 MR. CLARKE:

With what results? Could you show them and describe them, please?

354 DR. COTTON:

Both these samples are degraded to about the same extent. You have to look way down here at the bottom, and you see a smear of DNA here and you see a smear of DNA here and you see nothing up in this range here (Indicating). These two samples clearly are not good enough for RFLP testing.

355 MR. CLARKE:

And were they then tested using the PCR method?

356 DR. COTTON:

Yes.

357 MR. CLARKE:

With the results that you described last week?

358 DR. COTTON:

Yes.

359 MR. CLARKE:

Now, amongst these--first of all, have we now shown each of 47 through 50 and 52, each of the blood drops?

360 DR. COTTON:

Yes.

361 MR. CLARKE:

All right. Then perhaps, your Honor, we can remove or ask the witness to retake the stand and I'll ask her further questions.

362 THE COURT:

All right.

363 (The witness complies.)
364 MR. CLARKE:

Now, having shown these five samples, 47, 48, 49, 50 and 52, were you or can you summarize any differences in their relative amounts of DNA as revealed by these yield gels?

365 MR. NEUFELD:

Your Honor, objection. Asked and answered. That was the question immediately before this.

366 THE COURT:

Overruled.

367 DR. COTTON:

You can get a general idea from the gels that the amounts of DNA are pretty much in the same ballpark with the exception of 56. But again, because this isn't a measure of human DNA, this isn't a very good place to try to get quantitation as to a precise amount.

368 MR. CLARKE:

Okay. Let's turn to human DNA then with regard to these samples. What can you describe about that?

369 DR. COTTON:

That determination was made on a slot blot and that's another page of notes.

370 MR. CLARKE:

Okay. Is there a way that you can describe those results for us from these various items, 47 through 50 and 52?

371 DR. COTTON:

From the slot blot?

372 MR. CLARKE:

Yes.

373 DR. COTTON:

Sure.

374 MR. CLARKE:

Okay. Can we address these in order? That might be easier to follow. For instance, item no. 47?

375 DR. COTTON:

It's easier for you.

376 MR. CLARKE:

Would it be easier for you in a different order?

377 DR. COTTON:

Yeah.

378 MR. CLARKE:

Okay. Let's start with the one that's easiest to get to then.

379 DR. COTTON:

Uh--

380 THE COURT:

Why don't you pull the microphone closer.

381 DR. COTTON:

Oh, sorry. This quantitation is done from the PCR extraction, and the various amounts of DNA--what kind of answer are you looking for? Do you want nanograms or do you want like thoughts and not so much--

382 MR. CLARKE:

What would be the easiest way to describe any relative differences between these five drops?

383 DR. COTTON:

Well, I can tell you which ones had the most, which had a middle amount and which had nothing that we could detect.

384 MR. CLARKE:

All right. Why don't you do that.

385 DR. COTTON:

Okay. The samples that had the most DNA were 50 and item 52. The samples that had moderate amounts were 49 and 12, which I know wasn't--that's not on the--

386 MR. CLARKE:

12 was from the Rockingham residence, right?

387 DR. COTTON:

Right.

388 MR. CLARKE:

Okay.

389 DR. COTTON:

And then the samples that had no detectable DNA on here, which doesn't mean they don't have any, but it just means we're not detecting it, would be 56--

390 MR. NEUFELD:

Objection as to 56.

391 THE COURT:

Sustained.

392 DR. COTTON:

Oh, okay.

393 MR. CLARKE:

I believe you described 49, 50 and 52 thus far. Can you describe for us 47 and 48?

394 DR. COTTON:

Yes. 47 had no detectable, and for item 48, I think I have to go to another--I think I have to go to another film. Where can I find that? I have to go--I think I have to go to another film.

395 MR. CLARKE:

All right. Is that something that you can retrieve from your folder?

396 DR. COTTON:

I can, but I have to go back and figure out what sample number of mine it is.

397 MR. CLARKE:

You're looking for item no. 48; is that right?

398 DR. COTTON:

Right.

399 MR. CLARKE:

Would that be your item 12?

400 DR. COTTON:

Yes. And 12 also had no detectable DNA.

401 MR. CLARKE:

I'm sorry. Was that--when you say 12, what LAPD item--

402 DR. COTTON:

That's my item 12, your no. 48.

403 MR. CLARKE:

You described Los Angeles Police Department item no. 12, the Rockingham foyer, as having a moderate amount of DNA; is that right?

404 DR. COTTON:

In my scenario, I think it was a moderate amount. You're right.

405 MR. CLARKE:

Before we move on to a different area, are these differences that you've described amongst 47 through 52 consistent or inconsistent with cross-crontom--I'm sorry--cross-contamination transfer of DNA as posed by Mr. Neufeld in his hypothetical?

406 MR. NEUFELD:

Objection. No foundation. It's pure speculation at this point.

407 THE COURT:

Sustained.

408 MR. CLARKE:

Does the relative amounts--well, let me rephrase that. Do these results of the relative amounts of human DNA differ among these samples along the walkway drops?

409 DR. COTTON:

Yes.

410 MR. CLARKE:

Does that tell you anything or does that lead you to any opinions or conclusions about whether or not that DNA was transferred from other evidence items as opposed to being DNA collected in the locations as described?

411 MR. NEUFELD:

Objection again. No foundation, pure speculation.

412 THE COURT:

Rephrase the question.

413 MR. CLARKE:

Can I have just a moment?

414 THE COURT:

Sure.

415 (Discussion held off the record between the Deputy District Attorneys.)
416 MR. CLARKE:

Dr. Cotton, based on these differing levels of DNA in these various items, does that lead you to any opinion about whether or not the DNA detected in your testing is from material collected at a crime scene versus material transferred from stains during evidence processing?

417 MR. NEUFELD:

Objection. No foundation. Purely speculation.

418 THE COURT:

Overruled.

419 DR. COTTON:

It looks to me like--if it was a transfer, it would have had to been subsequently affected by the swatch it was transferred to. Otherwise, you have to--you have to postulate that it was--if it was a transfer, it wasn't from the same thing, it wasn't all from the same tube of blood or all from the same swatch because they're all different.

KEY QUOTE
420 MR. NEUFELD:

Move to strike, your Honor, that answer.

421 THE COURT:

Overruled.

422 MR. CLARKE:

Now, I'm going to shift topics, Dr. Cotton, if I could. You were asked a number of questions about packaging evidence items. Do you recall that?

423 THE COURT:

And I sustained most of the objections to those questions.

424 MR. CLARKE:

All right.

425 DR. COTTON:

Vaguely.

426 MR. CLARKE:

I'm not sure if I want to ask the next question or not.

427 THE COURT:

Let your conscience be your guide.

KEY QUOTE
428 MR. CLARKE:

Let's turn to plastic bags. Do plastic bags play any role in preventing cross-contamination?

429 DR. COTTON:

Of course they would.

430 MR. CLARKE:

How?

431 DR. COTTON:

You have one sample in a plastic bag and you have another sample in another plastic bag, it would be hard to get material from one sample onto the next sample.

432 MR. CLARKE:

When you discussed--and you were asked a few questions just this morning--may have been this afternoon, but I think it was this morning--about DNA, when you're talking about a bloodstain, is looking at or actually detects DNA that's contained in white blood cells; is that right?

433 DR. COTTON:

Yes.

434 MR. CLARKE:

DNA is not contained in red blood cells?

435 DR. COTTON:

That's correct.

436 MR. CLARKE:

You were also asked about some conventional serology techniques that type proteins such as--and I believe the slide actually had EAP on it; is that right?

437 DR. COTTON:

Yes.

438 MR. CLARKE:

Where does that protein obtain from in a bloodstain? Is it the white blood cells or something different?

439 DR. COTTON:

Uh, for EAP, it's red--I believe it's red blood cells.

440 MR. CLARKE:

Now, let's take--so it's different. In other words--

441 DR. COTTON:

It's a different cell type.

442 MR. CLARKE:

Red blood cells versus white blood cells for DNA; is that right?

443 DR. COTTON:

Yes.

444 MR. CLARKE:

In a bloodstain--and let's just take a bloodstain left at a crime scene--do the red blood cells go to some different location than the white blood cells or are they mixed?

445 DR. COTTON:

They're all mixed.

446 MR. CLARKE:

In other words, are they all floating around until a piece of blood is deposited on a surface?

447 DR. COTTON:

Yes.

448 MR. CLARKE:

What happens to the cells at that point, once a bloodstain is--I'm sorry--a blood drop is left on a surface of any kind?

449 DR. COTTON:

I don't--I don't know how to answer that question.

450 MR. CLARKE:

Well, let me focus it in a little bit if I can. Is it the case that those cells, white versus red, go to different locations in the blood stain or do they stay mixed?

451 DR. COTTON:

The blood is a mixture of cells and proteins and other things. I think for most practical purposes, you can think of it as a homogenous mixture, so that when the blood is deposited, it would still stay a mixture. I mean cells are very tiny. You know, they're just going to be distributed in the bloodstain, white and red together.

452 MR. CLARKE:

Now, I'm going to shift your attention again to just briefly about evidence that you received from the Los Angeles Police Department. Did you receive any extracted DNA from the LAPD?

453 DR. COTTON:

No.

454 MR. CLARKE:

You received only evidence items themselves in the form of swatches, bloodstain swatches or unstained controls as well as known samples; is that right?

455 DR. COTTON:

From LAPD, yes.

456 MR. CLARKE:

Where did you get any extracted DNA from?

457 DR. COTTON:

California Department of Justice lab.

458 MR. CLARKE:

As far as all of the Los Angeles Police Department evidence items, were all of the extractions done in your laboratory that were received by your laboratory, the evidence items?

459 DR. COTTON:

Yes.

460 MR. CLARKE:

Now, I would like to turn your attention if I could to a particular control that was described earlier today in the course of your PCR testing wherein there were some detectable DNA types. Do you recall that?

461 DR. COTTON:

Yes, I do.

462 MR. CLARKE:

First of all, that control--well, what kind of control was it?

463 DR. COTTON:

It was a reagent blank control.

464 MR. CLARKE:

And that's one of the controls you used to ensure that the test worked probably in a PCR test, right?

465 DR. COTTON:

Yes.

466 MR. CLARKE:

Can you tell us what evidence item number or numbers that particular control was a part of that same test?

467 DR. COTTON:

Yes. And I may have made an error this morning. Umm--

468 (Discussion held off the record between the Deputy District Attorneys.)
469 DR. COTTON:

That reagent blank control was started with--shall I just read the list?

KEY QUOTE
470 MR. CLARKE:

Well, first of all, what item--okay. How many--yes, if you would. That's probably the best way.

471 DR. COTTON:

Item 78, item 56, item 52, item 7, item 47, item 12. That control was started with those items. It was processed through with those items, and two of those items were also--two of those items didn't give any amplified product and were concentrated. After the concentration, one of them gave amplified product and the reagent blank gave two faint dots and the sample that was concentrated and then gave amplified product was item 56. And this morning, I think I was saying it was item 7, and that is not correct.

472 MR. CLARKE:

Now, these two faint dots that you've just described, did their existence affect the typing results of the items other than item no. 56?

473 DR. COTTON:

In our judgment, they did not affect the typing results because--okay. Think of--you do the extraction and you start the control. You bring it along and you type the samples and you type the control. For those samples that typed at that point, the control did not show any faint dots. And, therefore, we interpreted those samples. So that was a judgment call on our part. Two of those samples were then--going forward now, two of those samples were then concentrated and one of them gave a type and the control gave two faint dots. They--so it isn't that you have a whole type and the control, but you do have two faint dots. We made a judgment to report those results because the dots in the reagent blank were faint. Now, whether we type that sample again at the point before it was concentrated--that is, when I say the sample, I'm now referring to item 56--is something I'd have to look up because I was getting confused this morning.

474 MR. CLARKE:

Okay. With regard to the earlier samples, that control showed no reactions whatsoever with DNA types; is that right?

475 DR. COTTON:

At the first time that it was run, the controls showed no reaction. It did not show any reaction until it was put through the microconcentrator.

476 MR. CLARKE:

Okay. Let's talk about why in your view is it appropriate to type those, that is to report the results from all of those items that were a part of that control when that control showed some faint DNA detected when you concentrated it.

477 DR. COTTON:

Let's take the worse scenario and assume that the contamination was in that control from the beginning and also in the sample from the beginning. If that contamination is so small as to not produce a typeable result of any kind, whether or not it's there, it can't have affected the results.

478 MR. CLARKE:

All right. As far as the later typing of item no. 56, why is it appropriate to report the results when it in fact showed that small or faint detectable level of DNA?

479 DR. COTTON:

That's the question to give you the best answer. That's what I was confused on, whether or not we typed that sample again, and it might take me a minute to find that in the notes.

480 MR. CLARKE:

All right. Do you think it would take long or would you prefer to do it when you have more time?

481 DR. COTTON:

Uh, I'd actually rather do it when I had more time if you gave me a choice.

482 MR. CLARKE:

With regard to the remainder of your tests, was there any DNA detected in any of the other controls?

483 DR. COTTON:

No, there wasn't.

484 MR. CLARKE:

Well--

485 DR. COTTON:

In the positive controls, there was. But in the negative controls, there was no DNA depicted in any other negative control or any other reagent blank control run alongside any other sample that we did.

486 MR. CLARKE:

In other words, the remainder of the negative control showed nothing as far as controls not expected to show DNA?

487 DR. COTTON:

That's right.

488 MR. CLARKE:

Incidentally. You were shown a portion of your laboratory protocol today; is that right?

489 DR. COTTON:

Yes.

490 MR. CLARKE:

And I believe you were asked about a specific page that dealt with controls and decisions that are to be made based on, for instance, a negative control failing?

491 DR. COTTON:

Yes.

492 MR. CLARKE:

What is a failed control or control that failed? What does that mean?

493 DR. COTTON:

It's relatively vague. I mean, it's in the standard operating procedure, but I have to admit that that's a vague--basically--if you have any detectable DNA, you could say the control--I don't like this word "The control failed." If you have detectable DNA on that control, the control told you what you wanted it to tell you. It told you you might have a problem. It also may be telling you that you shouldn't interpret the results, that you should call them inconclusive, that you should do it again or you should think carefully before you give an interpretation.

494 MR. CLARKE:

As far as that control--and I believe you had started to describe earlier today about discretion in the laboratory; is that right?

495 DR. COTTON:

Yes.

496 MR. CLARKE:

On that particular page of your protocol, is there a provision giving Ph.D.s discretion to make certain decisions?

497 DR. COTTON:

Yes. We always--I mean, you would certainly want to do that. There's no way you could write a standard operating procedure that could describe every circumstance for every test that you could ever get. So if you don't allow room to use your--your judgment in analysis, then you wouldn't be giving the best possible analysis.

498 MR. CLARKE:

Do you exercise that discretion as a result of your education, training and experience as a DNA analyst?

499 DR. COTTON:

Well, I do and the other lab staff that are involved in the testing do as well.

500 MR. CLARKE:

With regard to this particular re--negative control that showed this faint DNA present, did you utilize your discretion to determine that those results should be reported?

501 DR. COTTON:

Yes, we did.

502 MR. CLARKE:

Incidentally, does your laboratory report results according to who's paying for your services?

503 DR. COTTON:

Of course not.

504 MR. CLARKE:

In your laboratory, is there an approximate percentage of number of cases in which, for instance, suspects are excluded?

505 DR. COTTON:

Yes.

506 MR. CLARKE:

What is that approximate percentage?

507 DR. COTTON:

The--

508 MR. NEUFELD:

Objection. Irrelevant, your Honor.

509 THE COURT:

Overruled.

510 DR. COTTON:

The approximate percent of cases in which we have an exclusion is about 30 percent.

511 MR. CLARKE:

I'm sorry. About what?

512 DR. COTTON:

About 30 percent.

513 MR. CLARKE:

What does that mean, when you report approximately 30 percent exclusions?

514 MR. NEUFELD:

Objection. Beyond the scope of cross-examination.

515 THE COURT:

Overruled. Goes to credibility. You can answer the question.

516 DR. COTTON:

It means that we've been asked to compare a victim or--let me back up. It means we've been asked to compare a known sample with an evidence sample. And if the known sample doesn't come from the evidence sample, then they are excluded as being a contributor. So depending on the nature of the evidence and the question that somebody else cares about, that's--can be an important piece of information.

517 MR. CLARKE:

Do you in your laboratory report results excluding certain suspects and report those results to Prosecutors who have asked you to do testing?

518 DR. COTTON:

Yes.

519 MR. CLARKE:

You have described, Dr. Cotton, the fact that in your laboratory, you don't test all genetic markers that are used in forensic science. And let's take an RFLP test for example. Is that right?

520 DR. COTTON:

That's right.

521 MR. CLARKE:

Why is that?

522 DR. COTTON:

We use five. We feel that that provides for the great majority of cases a sufficient amount of information to--that additional markers would sort of be like icing on the cake. Now, there are circumstances where more is necessary, in which case you'd have to go to another lab to get more. But for the most part, five markers or if you did five markers and the PCR markers, you have a very good amount of information there.

523 MR. CLARKE:

For instance--and let's take item no. 52 as an example. How many total genetic markers on that Bundy driveway stain did your laboratory test at?

524 DR. COTTON:

Five RFLP markers and six PCR markers.

525 MR. CLARKE:

Or a total of 11 different genetic markers?

526 DR. COTTON:

Yes.

527 MR. CLARKE:

Dr. Cotton, if you could--and I'm going to shift to one other area briefly. Could you tell us what LAPD evidence item numbers your laboratory actually performed the extraction and then typing process on? Can you list those for us?

528 DR. COTTON:

Sure.

529 MR. CLARKE:

Okay. Could you do that, please?

530 DR. COTTON:

What items we analyzed?

531 MR. CLARKE:

Exactly. Using--no. Actually extracted the DNA and then typed. In other words, you received an item of evidence, a swatch, and then extracted the DNA and then typed it.

532 THE COURT:

Haven't we already asked this question in a different way?

533 MR. CLARKE:

I have in--I'm sorry. I have in total, but not by individual item number. If I could, your Honor.

534 THE COURT:

All right.

535 DR. COTTON:

The easiest way I guess for me to do that is to go through the report or to, you know, move through the reports to do that.

536 MR. CLARKE:

Okay. Can we do that in relatively short order or not?

537 DR. COTTON:

It should be easy.

538 MR. NEUFELD:

Your Honor, also object. This is beyond the scope too.

539 THE COURT:

Overruled.

540 DR. COTTON:

As long as you don't want it in some special order.

541 MR. CLARKE:

No. If you can just list us the numbers, that would be fine.

542 DR. COTTON:

Shall I--shall I go ahead?

543 MR. CLARKE:

Yes.

544 DR. COTTON:

Item 49, item 50, the three blood exemplars which were labeled to us as c-1, c-2 and c-3, item 7, 12, 49--sorry--7, 12, 47, 52, 56, 78. I think I already said 49 and 50.

545 MR. CLARKE:

Yes.

546 DR. COTTON:

7. if I didn't already say 56, that's in there. If I didn't already say 48, which I think I did, that's in there.

547 MR. CLARKE:

Did you say item no. 48 also, Dr. Cotton?

548 DR. COTTON:

Yes. And then the four unstained swatches, no. 7 control, no. 12 control, number 49 and number 46.

549 MR. CLARKE:

Your Honor, I'm going to repeat, if I may, in chronological order what I believe to be those numbers. Would that be acceptable to the Court?

550 THE COURT:

Yes.

551 MR. CLARKE:

C-1--

552 MR. CLARKE:

And please stop me if I have any of these incorrectly, Dr. Cotton. The three knowns, c-1, c-2 and c-3?

553 DR. COTTON:

Yes.

554 MR. CLARKE:

Then items no. 7, 12, 47, 48, 49, 50, 52, 56, 78 and the four unstained controls, 7, 12, 49 and 56.

555 DR. COTTON:

Yes.

556 MR. CLARKE:

Does that sound right?

557 DR. COTTON:

That sounds right.

558 MR. CLARKE:

And those were items that Cellmark actually extracted and then typed?

559 DR. COTTON:

Yes.

560 MR. CLARKE:

Now, if I may, Dr. Cotton, I would like to turn your attention to the area of population frequencies. All right?

561 DR. COTTON:

Yes.

562 MR. CLARKE:

Why is it that you can test and use in your databases, say, 4- to 600 people and yet be able to make statements about rarity of types that obviously are not only higher than 4- to 600, but are in the millions or even billions?

563 MR. NEUFELD:

Objection. Twofold, your Honor. One, first, facts that are contrary to her testimony as to the size and, two, there's no foundation.

564 THE COURT:

Sustained. Rephrase the question.

565 MR. CLARKE:

With regard to the number of individuals in your databases, approximately how many are there total?

566 DR. COTTON:

Somewhere around--somewhere around 5- to 600 total.

567 MR. CLARKE:

You utilize those databases to create--not to create--to report population frequency data; is that right?

568 DR. COTTON:

That's right.

569 MR. CLARKE:

And you've in fact done that in this case; is that right?

570 DR. COTTON:

Yes, we have.

571 MR. CLARKE:

As far as these RFLP results, several of them are in the millions or even billions; is that right?

572 DR. COTTON:

Yes.

573 MR. CLARKE:

How can you take numbers of 4- to 5- to 600 of people in these databases and be able to determine estimates of frequency that are numbers higher than 5- or 600? Do you understand my question?

574 DR. COTTON:

I do. Let me give you several different pieces to that answer. First of all, we are relying on work done by other scientists knowledgeable about RFLP alleles; that is, how many of them there are to give us some estimation, statistical estimation of how large a database is needed.

575 MR. NEUFELD:

As to that, your Honor, I move to strike as to the hearsay representations of other people.

576 THE COURT:

Overruled.

577 DR. COTTON:

Secondly, the--keep in mind now it's impossible to test everyone and it is actually relatively time-consuming to even test 5- or 600 people given that you can get about 15 people on one gel. You can develop a sample size--a sample and make an estimate--make an estimation from that sample. And, again, the critical word here is "estimation." You could then go out and get another sample or another group to get another sample. And if this were a legitimate thing to be doing, you could say, does the distribution of frequencies, that is, how often I see a band at 5,000 and how often I see one at 6- and the whole distribution of how often you see a particular allele, does it look like other samples from the same racial group from another part of the country. It will not look the same, but it should look similar.

578 MR. NEUFELD:

Objection. Objection, your Honor. Again, move to strike as to other databases.

579 THE COURT:

Speaking objection. Overruled. Ask another question.

580 MR. CLARKE:

With regard to this process--and you've described now looking at--I'm sorry--at other information?

581 DR. COTTON:

Yes. We do look at other information.

582 MR. CLARKE:

What is that?

583 DR. COTTON:

Some of the other information has come--well, it's come from various sources. There's information about our probes and our enzyme from a few sources in the United States, from many sources in Europe. There is information that's been compiled for the FB--by the FBI, a very large amount of information looking at a different restriction enzyme, but--and a panel of probes, several of which overlap with ours and several of which don't. The overall--

584 MR. NEUFELD:

Your Honor, again, I'm going to have to object as to no discovery.

585 THE COURT:

Overruled. Proceed.

586 MR. CLARKE:

You can continue, Dr. Cotton.

587 THE COURT:

No. Ask another question. This is a narrative.

588 MR. CLARKE:

All right. You looked at other items and you described a study by the FBI?

589 DR. COTTON:

Say that again?

590 MR. CLARKE:

You've described the fact that you looked at other information. In particular, you were describing a study done by the FBI?

591 DR. COTTON:

Yes.

592 MR. CLARKE:

Is that a fairly large study?

593 DR. COTTON:

It's very large.

594 MR. CLARKE:

And what did it look at?

595 DR. COTTON:

It looked at RFLP databases generated by various laboratories across the country and made comparisons as to the distribution of alleles from databases that were generated in various places at the various racial groups.

596 MR. CLARKE:

What's the significance of those findings as far as what I asked you about, taking databases and then making estimations that are in the millions or even billions?

597 MR. NEUFELD:

Objection. Move to strike, your Honor.

598 THE COURT:

What's the objection?

599 MR. NEUFELD:

Your Honor, there's absolutely no foundation.

600 THE COURT:

Overruled.

601 MR. NEUFELD:

And also, no discovery.

602 THE COURT:

Overruled.

603 MR. NEUFELD:

And hearsay.

604 THE COURT:

Overruled.

605 DR. COTTON:

What it tells you is that if you take a rac--a database from one part of the country for Caucasians, blacks or Hispanics and you compare it to a database from some other part of the country and you generated a profile frequency, that the frequencies are very, very similar. There are not large differences in the samples from one part of the country to the next.

606 MR. NEUFELD:

Objection. Move to strike as to "similar," as to "they."

607 THE COURT:

Overruled.

608 MR. CLARKE:

You have described using RFLP typing at five probes, for instance, with regard to the Bundy stain, no. 52, and the boot drop, no. 78?

609 DR. COTTON:

Yes.

610 MR. CLARKE:

When you make these estimations of frequency--and I believe you touched a little bit on a concept called independence?

611 DR. COTTON:

Yes, I did.

612 MR. CLARKE:

And what is that again?

613 DR. COTTON:

It means whether or not you inherit one allele that you have is not--does not affect the second allele that you might get. That is, if you inherit a band at 5,000 base pairs, that doesn't mean you'll automatically or with some probability inherit on at 6,000. What you inherit from one parent is what you inherit from the other.

614 MR. CLARKE:

Why is that important?

615 DR. COTTON:

Mathematically that's important because if that were not the case, it would be improper to multiply the frequencies between the different genetic locations.

616 MR. CLARKE:

How do you--well, first of all, are these markers independent that you've described in your testing in this case?

617 MR. NEUFELD:

Objection. Beyond this witness'--well, no foundation for this witness.

618 THE COURT:

We've gone beyond. We've already covered this once before. I know it was not directly touched upon in cross-examination.

619 MR. CLARKE:

I'm sorry?

620 THE COURT:

It was not directly touched upon in cross-examination.

621 MR. CLARKE:

All right.

622 MR. CLARKE:

Dr. Cotton, do you have a database for each community of the United States?

623 DR. COTTON:

No.

624 MR. CLARKE:

Why not?

625 DR. COTTON:

We'd have to have a lot bigger staff. It's not possible.

626 MR. CLARKE:

Do you need a database for each community of the United States to be able to estimate these frequencies?

627 MR. NEUFELD:

Objection. Beyond--foundation.

628 THE COURT:

Overruled.

629 DR. COTTON:

No.

630 MR. CLARKE:

Why?

631 DR. COTTON:

For all the reasons that I just talked about in the last several questions.

632 MR. CLARKE:

Do those include, for instance, these studies that you've described of groups of people in different parts of the United States and the world?

633 MR. NEUFELD:

Objection. Asked and answered and leading.

634 THE COURT:

Sustained.

635 MR. CLARKE:

When you say--I'm sorry?

636 THE COURT:

It's leading.

637 MR. CLARKE:

When you say the material that you have--I'm sorry. When you say specifically for the reasons that you give earlier--given earlier, can you tell us briefly what those reasons were?

638 MR. NEUFELD:

Objection. Asked and answered.

639 THE COURT:

Sustained. She's already told us what she's relied on.

640 MR. CLARKE:

Okay.

641 MR. CLARKE:

These frequencies that you've reported in this case, are they accurate in terms of being precise or are they estimates?

642 DR. COTTON:

They are estimates.

643 MR. CLARKE:

These numbers that you've reported, do they tell anything or do they have any relation whatsoever to the facts of this case? And I'm talking about the facts other than DNA.

644 DR. COTTON:

No.

645 MR. CLARKE:

Are they estimations only of what--of how common or how rare the various DNA types are that you obtained in your testing in your lab for all of the samples that you've described in your testimony?

646 DR. COTTON:

They are only estimates, which give you a conceptualization of how common or rare the collection of genetic markers is.

647 MR. CLARKE:

Do they in any manner take into account at all all of the other facts of this case that show what happened in this case?

648 DR. COTTON:

They don't take into account anything except saying is this collection of genetic types common or rare or somewhere in between. That is the only thing that those numbers tell you. They tell you nothing else.

649 MR. CLARKE:

All right. Your Honor, with the exception of the one area the witness asked to have a little time to look up, I'm concluded with my redirect at this time.

Temperature

procedural

Key Quotes (5)

Dr. Robin Cotton
There are no false positives and no incorrect exclusions in the remainder of those samples since 1989.
Directly rehabilitates the lab's credibility after cross-examination attacks on proficiency testing.
Dr. Robin Cotton
47, 48, 49 and 50 are consistent in type with Mr. Simpson. 56 is consistent in type with Nicole Brown. So if all of those samples were contaminated, they couldn't have all been contaminated from the same source.
Logical refutation of blanket cross-contamination theory — different types rule out a single contaminating source.
Dr. Robin Cotton
It looks to me like--if it was a transfer, it would have had to been subsequently affected by the swatch it was transferred to. Otherwise, you have to postulate that it was--if it was a transfer, it wasn't from the same thing, it wasn't all from the same tube of blood or all from the same swatch because they're all different.
Cotton's bottom-line opinion that the varying DNA levels are inconsistent with a single contamination event.
Lance A. Ito
Let your conscience be your guide.
Rare moment of judicial wit, addressed to Clarke when he hesitated about whether to ask a packaging question after Ito noted he'd sustained most such questions earlier.
Dr. Robin Cotton
That reagent blank control was started with those items... this morning, I think I was saying it was item 7, and that is not correct.
Voluntary correction of morning testimony — Cotton clarifying item 56, not item 7, was concentrated before the reagent blank showed faint dots.

Evidence (9)

People's 259
Bundy crime scene DNA results board listing items 47-56 and 78
displayed to jury during questioning
People's 263
Photograph of yield gel (mini gel) showing DNA quality for items 78, 56, 52, 7, 47, and 12 — dated 8-1-94
introduced and explained lane by lane
People's 264
Photograph of second yield gel showing DNA quality for items 49 and 50
introduced and explained
Informal
LAPD items 47, 48, 49, 50, 52 — Bundy walkway blood drops
discussed extensively; DNA degradation levels compared
Informal
LAPD item 56 — shoeprint at Bundy
discussed; typed to Nicole Brown, distinguishing it from Simpson-consistent drops
Informal
LAPD item 78 — boot drop at Bundy
discussed; DNA quality assessed as good enough for RFLP
+ 3 more

Notable Exchanges (4)

George ClarkeDr. Robin Cotton
Clarke led Cotton through a multi-step logical dismantling of Neufeld's cross-contamination hypothetical: each walkway drop would have had to independently degrade to undetectable, then receive sufficient high-quality DNA from a separate source, then show different levels of DNA quality — all of which Cotton confirmed would be necessary but is contradicted by the actual varying results.
strategic
George ClarkeDr. Robin Cotton
Clarke displayed yield gel photographs and had Cotton walk the jury lane by lane through DNA degradation patterns, distinguishing the 'very degraded' drops (47, 49, 50) from the moderately degraded item 52 which still yielded an RFLP result.
methodical
Dr. Robin CottonGeorge Clarke
Cotton volunteered a correction to her morning testimony, clarifying that the reagent blank showing two faint dots was run with item 56 (not item 7 as she had said), and that item 56's concentration step preceded the blank result.
revealing
Lance A. ItoGeorge Clarke
After Clarke expressed uncertainty about asking a packaging question — noting that Ito had sustained most such questions earlier — the judge quipped 'Let your conscience be your guide,' prompting Clarke to pivot to plastic bags instead.
light

Light Moments (2)

Lance A. Ito
After Clarke hesitated about a packaging question, noting the judge had sustained most related objections, Ito quipped 'Let your conscience be your guide.'
Dr. Robin Cotton
When Clarke asked Cotton to describe relative DNA amounts, she replied 'It's easier for you' when he suggested going in item-number order, then asked what kind of answer he was looking for — nanograms or 'like thoughts.'

Credibility Attacks (2)

⚔ Cellmark Diagnostics / Dr. Cotton
proficiency test record — prior cross-examination
Clarke used redirect to affirmatively establish that across 104 tests and 466 samples since 1989, Cellmark produced zero false positives and zero incorrect exclusions, rehabilitating after Neufeld's cross on proficiency testing.
⚔ Dr. Robin Cotton
prior inconsistent statement
Cotton voluntarily corrected her own morning testimony, clarifying she had incorrectly identified item 7 (rather than item 56) as the sample concentrated before the reagent blank showed faint dots.

Witness Demeanor

(The witness complies.) — multiple instances retrieving notes and photographs from folder
(Brief pause.) — while exhibit board was positioned
(Discussion held off the record between the Deputy District Attorneys.) — multiple instances Clarke conferring mid-examination
(Discussion held off the record between the Deputy District Attorney and the witness.) — while organizing gel photographs

Objections

16 objections (6 sustained, 10 overruled)
Proceeding 6045 • 649 utterances • Prosecution witness
Criminal Trial
Department 103
⚖️ Start
📂 MAY 15, 1995 📄 Redirect examination of Dr. Ro
MAY 15, 1995 KRT DvH TD